Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06416969 · ClinicalTrials.gov registry record · Early Phase 1
Regional Lipolysis and Adipocyte Lipolysis Protein Stimulation
A Early Phase 1 study of Obesity, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT06416969 is a Early Phase 1 study of Obesity that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 24 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06416969, a Early Phase 1 study of Obesity, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
Adults who gain most of their excess weight in the abdominal area typically do not respond to factors that "turn on" fat cells the same way as people who don't have excessive weight. Researchers are trying to understand why fat tissue responds differently in people with different body types.
Conditions Studied
Interventions
- DRUG Somatostatin
- DRUG Epinephrine
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-01-01 |
| Est. Completion | 2027-04-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06416969
The ClinicalTrials.gov registry entry for NCT06416969 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (97% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Somatostatin is the first listed.
NCT06416969 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT06416969 about?
NCT06416969 is a clinical study titled "Regional Lipolysis and Adipocyte Lipolysis Protein Stimulation". Adults who gain most of their excess weight in the abdominal area typically do not respond to factors that "turn on" fat cells the same way as people who don't have excessive weight. Researchers are trying to understand why fat tissue responds differently in people with different body types.
What is the current status of trial NCT06416969?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2024-01-01. Estimated completion is 2027-04-01.
What conditions does trial NCT06416969 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT06416969?
The interventions under investigation include: Somatostatin (DRUG), Epinephrine (DRUG).
Who is sponsoring clinical trial NCT06416969?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06416969 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension
RECRUITING · Early Phase 1
-
Social Determinants of Sleep and Obesity
RECRUITING · Early Phase 1
-
Effect of Tirzepatide on Markers of MASLD in Patients With Obesity
RECRUITING · Early Phase 1
-
Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues
RECRUITING · Early Phase 1
-
Evaluation of Milk Polar Lipids in Dyslipidemic Adults With Abdominal Obesity
RECRUITING · Early Phase 1
-
Sympathetic Transduction in Obesity-associated Hypertension (OB-HTN)
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.